Biotech drug pharmacokinetics MCQs With Answer

Introduction

This set of MCQs on Biotech Drug Pharmacokinetics is tailored for M.Pharm students studying Advanced Biopharmaceutics & Pharmacokinetics (MPH 202T). The questions emphasize mechanistic principles governing absorption, distribution, metabolism and elimination of biologics such as monoclonal antibodies, peptides, oligonucleotides and antibody–drug conjugates. Topics include FcRn-mediated recycling, target-mediated drug disposition (TMDD), lymphatic uptake after subcutaneous dosing, immunogenicity (ADA) effects, bioanalytical challenges and PK/PD modeling strategies used for dose selection and prediction across species. Each MCQ is designed to test conceptual understanding and clinical translational skills necessary for developing and evaluating biotech therapeutics.

Q1. Which primary pathway is responsible for systemic absorption of monoclonal antibodies after subcutaneous administration?

• Transcellular passive diffusion across capillary endothelium
• Paracellular diffusion through tight junctions
• Lymphatic uptake and transport into systemic circulation
• First-pass hepatic uptake from the injection site

Correct Answer: Lymphatic uptake and transport into systemic circulation

Q2. Typical apparent volume of distribution (Vd) for full-length IgG monoclonal antibodies in adults is closest to which of the following?

• Approximately 3–6 liters (limited to plasma and interstitial space)
• Approximately 40–60 liters (total body water)
• Approximately 200–400 liters (extensive tissue distribution)
• Less than 1 liter (strictly plasma confined)

Correct Answer: Approximately 3–6 liters (limited to plasma and interstitial space)

Q3. The neonatal Fc receptor (FcRn) extends IgG half-life chiefly by which mechanism?

• Promoting hepatic glucuronidation
• Facilitating renal reabsorption in the proximal tubule
• Binding IgG in endosomes and rescuing it from lysosomal degradation
• Inhibiting proteases in plasma

Correct Answer: Binding IgG in endosomes and rescuing it from lysosomal degradation

Q4. Target-mediated drug disposition (TMDD) for biologics is characterized by which pharmacokinetic behavior?

• Linear, dose-proportional clearance at all concentrations
• Saturable, nonlinear clearance at low to moderate concentrations due to high-affinity target binding
• First-order renal elimination only
• Elimination exclusively by biliary excretion

Correct Answer: Saturable, nonlinear clearance at low to moderate concentrations due to high-affinity target binding

Q5. PEGylation of therapeutic proteins most commonly results in which PK change?

• Increased renal filtration and faster clearance
• Marked increase in tissue penetration into CNS
• Increased hydrodynamic radius leading to reduced renal clearance and prolonged half-life
• Complete elimination of immunogenicity

Correct Answer: Increased hydrodynamic radius leading to reduced renal clearance and prolonged half-life

Q6. The presence of anti-drug antibodies (ADA) against a monoclonal antibody typically leads to which pharmacokinetic consequence?

• Decreased clearance and prolonged half-life
• No change in pharmacokinetics but increased potency
• Increased clearance and reduced systemic exposure
• Universal neutralization without affecting pharmacokinetics

Correct Answer: Increased clearance and reduced systemic exposure

Q7. Which bioanalytical technique is most commonly used for sensitive quantification of therapeutic proteins in plasma during PK studies?

• Gas chromatography–mass spectrometry (GC–MS)
• Ligand-binding assays (e.g., ELISA or ECL)
• Capillary electrophoresis
• Infrared spectroscopy

Correct Answer: Ligand-binding assays (e.g., ELISA or ECL)

Q8. When TMDD pathways are saturated at high doses of a monoclonal antibody, the clearance typically becomes:

• More nonlinear and concentration-dependent
• Highly time-dependent but not dose-dependent
• Approximately linear and concentration-independent
• Zero-order at all concentrations

Correct Answer: Approximately linear and concentration-independent

Q9. Molecules above which approximate molecular weight predominantly rely on lymphatic uptake rather than direct capillary absorption after subcutaneous injection?

• Less than 1 kDa
• Approximately 5 kDa
• Approximately 16 kDa
• Over 500 kDa only

Correct Answer: Approximately 16 kDa

Q10. Fc engineering to extend antibody half-life should ideally increase FcRn affinity at which pH condition while maintaining low affinity at which other pH?

• Increase at pH 7.4 and maintain low at pH 6.0
• Increase at acidic endosomal pH (~6.0) while retaining low affinity at physiological pH (~7.4)
• Increase at both pH 6.0 and 7.4 equally
• Decrease affinity at both pH levels

Correct Answer: Increase at acidic endosomal pH (~6.0) while retaining low affinity at physiological pH (~7.4)

Q11. The predominant clearance mechanism for full-length monoclonal antibodies is:

• Hepatic cytochrome P450–mediated metabolism
• Glomerular filtration with urinary excretion of intact antibody
• Cellular uptake followed by intracellular proteolytic catabolism (lysosomal degradation)
• Biliary excretion of unchanged protein

Correct Answer: Cellular uptake followed by intracellular proteolytic catabolism (lysosomal degradation)

Q12. Typical absolute bioavailability range following subcutaneous administration for many monoclonal antibodies is closest to which interval?

• 5%–15%
• 25%–40%
• 50%–80%
• 90%–100%

Correct Answer: 50%–80%

Q13. Which modeling approach is most appropriate to quantify between-subject variability and covariate effects on PK for biologics in clinical populations?

• Noncompartmental analysis only
• Population PK using nonlinear mixed-effects modeling (NLME)
• Simple one-compartment deterministic modeling without variability terms
• Descriptive statistics of mean concentrations only

Correct Answer: Population PK using nonlinear mixed-effects modeling (NLME)

Q14. Antibody–drug conjugates (ADCs) deliver cytotoxic payloads to tumors. The predominant mechanism releasing the payload is:

• Passive diffusion of intact ADC across the cell membrane releasing payload extracellularly
• Internalization of ADC into target cells followed by lysosomal proteolysis or linker cleavage to release the payload
• Direct renal cleavage of the linker in circulation
• Spontaneous nonenzymatic degradation only in plasma

Correct Answer: Internalization of ADC into target cells followed by lysosomal proteolysis or linker cleavage to release the payload

Q15. Why are full-length monoclonal antibodies generally not eliminated by glomerular filtration?

• They are highly lipophilic and sequestered in tissues
• Their molecular size (~150 kDa) exceeds the glomerular filtration cutoff (~60 kDa)
• They are actively secreted into bile instead
• They are completely metabolized in the GI tract before reaching kidneys

Correct Answer: Their molecular size (~150 kDa) exceeds the glomerular filtration cutoff (~60 kDa)

Q16. Neutralizing anti-drug antibodies primarily affect which aspect of a biologic therapeutic?

• Only analytical assay detection without clinical consequence
• Reduce pharmacodynamic effect by blocking target binding, potentially reducing efficacy
• Always increase half-life of the therapeutic
• Only enhance tissue distribution without affecting efficacy

Correct Answer: Reduce pharmacodynamic effect by blocking target binding, potentially reducing efficacy

Q17. Which local physiological factor most strongly influences the rate of absorption from a subcutaneous depot for large proteins?

• Hepatic blood flow
• Lymphatic flow and transport from the injection site
• Gastric emptying rate
• Renal plasma flow

Correct Answer: Lymphatic flow and transport from the injection site

Q18. For accurate estimation of terminal half-life of a long‑acting monoclonal antibody, plasma sampling should generally continue for at least how many half-lives?

• Less than 1 half-life
• Approximately 1–2 half-lives
• Approximately 3–5 half-lives
• Only during absorption phase is sufficient

Correct Answer: Approximately 3–5 half-lives

Q19. A major bioanalytical challenge unique to quantifying therapeutic monoclonal antibodies in clinical samples is:

• Complete absence of endogenous interfering proteins
• Interference from high background of endogenous IgG and soluble target that can affect assay specificity
• Low molecular weight causing rapid volatilization
• Inability to detect any signal at therapeutic concentrations

Correct Answer: Interference from high background of endogenous IgG and soluble target that can affect assay specificity

Q20. For predicting human pharmacokinetics of a biologic that exhibits TMDD, the most appropriate translational modeling approach is:

• Simple linear allometric scaling of clearance without target considerations
• Mechanistic TMDD modeling (possibly integrated with physiologically based PK) that accounts for target binding, turnover and internalization
• Empirical one-compartment modeling in rodents extrapolated directly by dose
• Using only noncompartmental mean exposures from animals without modeling

Correct Answer: Mechanistic TMDD modeling (possibly integrated with physiologically based PK) that accounts for target binding, turnover and internalization

Download